The purpose of this study was to determine whether asthma control and reduced bronchial
responsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids
with ADVAIR DISKUS BID or FP BID in adult and adolescent patients with persistent asthma
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
GSK Investigational Site, Rio de Janeiro 21941-590, Brazil
GSK Investigational Site, São Paulo, Brazil
GSK Investigational Site, Sofia 1431/1000, Bulgaria
GSK Investigational Site, Varna 9010, Bulgaria
GSK Investigational Site, San Juan 00921, Puerto Rico
GSK Investigational Site, Birmingham, Alabama 35294-0012, United States
GSK Investigational Site, Jasper, Alabama 35501, United States
GSK Investigational Site, Glendale, Arizona 85304, United States
GSK Investigational Site, Tucson, Arizona 85724, United States
GSK Investigational Site, Huntington Beach, California 92647, United States
GSK Investigational Site, Long Beach, California 90806, United States
GSK Investigational Site, Los Angeles, California 90025, United States
GSK Investigational Site, Los Angeles, California 90048, United States
GSK Investigational Site, Los Angeles, California 90095-1752, United States
GSK Investigational Site, Pueblo, Colorado 81008, United States
GSK Investigational Site, Wheat Ridge, Colorado 80033, United States
GSK Investigational Site, Aventura, Florida 33180, United States
GSK Investigational Site, Jacksonville, Florida 32207, United States
GSK Investigational Site, Longwood, Florida 32750, United States
GSK Investigational Site, Tampa, Florida 33609, United States
GSK Investigational Site, Tampa, Florida 33613, United States
GSK Investigational Site, Coeur D'Alene, Idaho 83814, United States
GSK Investigational Site, Oak Brook, Illinois 60523, United States
GSK Investigational Site, South Bend, Indiana 46617, United States
GSK Investigational Site, Des Moines, Iowa 50309-1426, United States
GSK Investigational Site, North Dartmouth, Massachusetts 02747, United States
GSK Investigational Site, Livonia, Michigan 48152, United States
GSK Investigational Site, Chesterfield, Missouri 63017, United States
GSK Investigational Site, Omaha, Nebraska 68198-2456, United States
GSK Investigational Site, Mineola, New York 11501, United States
GSK Investigational Site, Charlotte, North Carolina 28207, United States
GSK Investigational Site, Wilmington, North Carolina 28401, United States
GSK Investigational Site, Winston-Salem, North Carolina 27103, United States
GSK Investigational Site, Cincinnati, Ohio 45231, United States
GSK Investigational Site, Cleveland, Ohio 44195, United States
GSK Investigational Site, Toledo, Ohio 43614-5809, United States
GSK Investigational Site, Eugene, Oregon 97401, United States
GSK Investigational Site, Lake Oswego, Oregon 97035, United States
GSK Investigational Site, Upland, Pennsylvania 19013, United States
GSK Investigational Site, Florianopolis, Santa Catarina 88040970, Brazil
GSK Investigational Site, Spartanburg, South Carolina 29303, United States
GSK Investigational Site, Dallas, Texas 75231-4307, United States
GSK Investigational Site, Dallas, Texas 75231, United States
GSK Investigational Site, Friendswood, Texas 77546, United States
GSK Investigational Site, Houston, Texas 77030, United States
GSK Investigational Site, Danville, Virginia 24541, United States
GSK Investigational Site, Richmond, Virginia 23229, United States
GSK Investigational Site, Bellingham, Washington 98226, United States
GSK Investigational Site, Seattle, Washington 98105, United States
GSK Investigational Site, Madison, Wisconsin 53792, United States
GSK Investigational Site, Milwaukee, Wisconsin 53209-0996, United States
Stauffer JL, Yancey SW, Baitinger LA, Prillaman BA, Dorinsky PM. Measuring airway hyperresponsiveness: Does it add to routine measures of clinical efficacy in guiding asthma therapy? Proc Am Thorac Soc 2006;3:A213